Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04151667 · OUTCOME

Number of Participants Who Continue on Arm A After 2 Cycles

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma · Source last updated 2026-08-20

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
At the end of Cycle 2 (each cycle is 28 days)

What was measured

The number of participants who continue on Daratumumab and Dexamethasone after 2 cycles

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denom Units Selected
Participants
description
The number of participants who continue on Daratumumab and Dexamethasone after 2 cycles
reporting Status
NOT_POSTED
time Frame
At the end of Cycle 2 (each cycle is 28 days)
title
Number of Participants Who Continue on Arm A After 2 Cycles
type
OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice